Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
5. Performance status (PS) score of 0-1, with an expected survival period of more than 3 months.
6. Age between 18 and 75 years old.
7. Assessment by PET-CT (including FDG and FMISO, not mandatory).
8. No contraindications to immunotherapy and radiotherapy.
9. Signed the informed consent form.
You may not be if
1. Those with severe dysfunction of important vital organs (heart, liver, kidney).
2. Those accompanied by other malignant tumors.
3. Uncontrolled heart diseases or myocardial infarction within the past 6 months.
4. Those with a history of mental illness.
5. Other situations in which the researcher deems it inappropriate for the subject to participate in the study.
Clareo Health | Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
